Market Research Logo

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023

“The global biosimilars market projected to grow at a CAGR of 31.7% during the forecast period.”
The biosimilars market is expected to reach USD 23.63 billion by 2023 from USD 5.95 billion in 2018, at a CAGR of 31.7%. Factors driving the growth of this market include increasing demand for biosimilar drugs due to their cost-effectiveness, rising incidence of chronic diseases, and strategic collaborations resulting in enhanced productivity and clinical trial activities.

“The recombinant glycosylated protein segment is anticipated to grow at the fastest growth rate during the forecast period.”
The biosimilars market by product is categorized into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant glycosylated proteins segment is expected to register the highest CAGR during the forecast period. The factors driving the market for glycosylated proteins are the broad therapeutic area of these proteins; presence of biosimilar versions of monoclonal antibodies at lower prices compared to reference products; numerous biologic drugs underclass monoclonal antibody, follitropin, and erythropoietin going off-patent; and numerous products in the pipeline.

“The contract manufacturing segment is estimated to grow at a rapid rate during the analysis period.”
By type of manufacturing, the biosimilars market is segmented into in-house manufacturing and contract manufacturing. The contract manufacturing segment is expected to grow at the highest CAGR during the forecast period. CMOs provide cost-saving benefits to companies in terms of facilities, equipment, and labor costs.

“Asia is estimated to register the highest CAGR during the study period.”
On the basis of region, the biosimilars market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR during the forecast period. Many Asian countries such as India, China, South Korea, and Japan have emerged as potential markets for biosimilars. Many emerging economies in the region are also establishing biosimilar pathways. Moreover, leading market players are outsourcing manufacturing and R&D activities to countries in the Asia Pacific region due to the availability of highly skilled resources at lower costs. In addition to this, the low per capita consumption, rapid growth in economies, trade links, and the rise in medical tourism are accelerating the growth of the Asian market.

The primary interviews conducted for this report can be categorized as follows:
By Company Type - Tier 1 - 70% and Tier 2 - 30%
By Designation - C-level - 62%, Director-level - 21%, Others - 17%
By Region - North America - 50%, Europe - 20%, Asia- 30%

The key players in the biosimilars market include Pfizer (US), Sandoz (Germany), Teva Pharmaceuticals (Israel), Amgen (US), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), and Samsung Biologics

Research Coverage:
The report analyses the biosimilars market by products, type of manufacturing, disease, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.

Key benefits of buying the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms, garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:
Market Penetration: Comprehensive information on the product portfolios of the top players in the biosimilars market
Product Development/Innovation: Detailed insights on product approvals, R&D activities, and product launches in the biosimilars market
Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the biosimilars market
Market Development: Comprehensive information about emerging markets. This report analyzes the market for various biosimilars across geographies
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market


  • INTRODUCTION
    • OBJECTIVES OF THE STUDY
    • MARKET DEFINITION
    • MARKET SCOPE
      • MARKET COVERED
    • YEARS CONSIDERED FOR THE STUDY
    • CURRENCY
    • LIMITATIONS
    • STAKEHOLDERS
  • RESEARCH METHODOLOGY
    • SECONDARY DATA
      • SECONDARY SOURCES
    • PRIMARY DATA
      • PRIMARY SOURCES
    • MARKET SIZE ESTIMATION
      • BOTTOM-UP APPROACH
      • TOP-DOWN APPROACH
    • DATA TRIANGULATION METHODOLOGY
    • ASSUMPTIONS FOR THE STUDY
  • EXECUTIVE SUMMARY
  • PREMIUM INSIGHTS
    • BIOSIMILARS MARKET OVERVIEW
    • ASIA: BIOSIMILARS MARKET, BY TYPE OF PRODUCT
    • BIOSIMILARS MARKET, BY REGION
    • GEOGRAPHICAL SNAPSHOT: BIOSIMILARS MARKET (MAJOR COUNTRIES)
  • MARKET OVERVIEW
    • INTRODUCTION
    • MARKET DYNAMICS
      • DRIVERS
        • Table MAJOR COLLABORATIONS IN THE BIOSIMILARS MARKET (2015–2018)
      • RESTRAINTS
      • OPPORTUNITIES
        • Table LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY
      • CHALLENGES
  • REGULATORY OUTLOOK
    • NORTH AMERICA
      • US
      • CANADA
        • Table STATUS OF REGULATORY PATHWAY IN NORTH AMERICA
    • EUROPE
      • Table SUBSTITUTION STATUS IN EUROPEAN COUNTRIES
    • ASIA PACIFIC
      • CHINA
      • INDIA
      • JAPAN
      • SOUTH KOREA
        • Table STATUS OF REGULATORY PATHWAY IN ASIA PACIFIC
    • REST OF THE WORLD
      • BRAZIL
      • MEXICO
      • ARGENTINA
      • SAUDI ARABIA
        • Table STATUS OF REGULATORY PATHWAY IN THE ROW
  • BIOSIMILARS MARKET, BY PRODUCT
    • INTRODUCTION
      • Table BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
    • RECOMBINANT NON-GLYCOSYLATED PROTEINS
      • Table BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
      • Table BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2016–2023 (USD MILLION)
      • RECOMBINANT HUMAN GROWTH HORMONE (RHGH)
        • Table BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2016–2023 (USD MILLION)
      • GRANULOCYTE COLONY-STIMULATING FACTOR (FILGRASTIM)
        • Table LIST OF APPROVED BIOSIMILARS FOR GRANULOCYTE COLONY-STIMULATING FACTOR PRODUCTS FROM 2013 TO 2016
        • Table BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2016–2023 (USD MILLION)
      • INSULIN
        • Table BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2016–2023 (USD MILLION)
      • INTERFERONS
        • Table BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE, 2016–2023 (USD MILLION)
        • Table BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2016–2023 (USD MILLION)
        • Table BIOSIMILARS MARKET FOR INTERFERON-BETA , BY REGION, 2016–2023 (USD MILLION)
        • Table BIOSIMILARS MARKET FOR INTERFERON-ALPHA, BY REGION, 2016–2023 (USD MILLION)
    • RECOMBINANT GLYCOSYLATED PROTEINS
      • Table BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD BILLION)
      • ERYTHROPOIETIN (EPO)
        • Table LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
        • Table BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 2016–2023 (USD MILLION)
      • MONOCLONAL ANTIBODIES (MABS)
        • Table BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016–2023 (USD BILLION)
        • Table BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2016–2023 (USD MILLION)
        • Table PIPELINE OF INFLXIMAB
        • Table BIOSIMILARS MARKET FOR INFLXIMAB, BY REGION, 2016–2023 (USD MILLION)
        • Table PIPELINE OF RITUXIMAB
        • Table BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2016–2023 (USD MILLION)
        • Table PIPELINE OF ADLIMUMAB
        • Table BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2016–2023 (USD MILLION)
        • Table PIPELINE OF OTHER MONOCLONAL ANTIBODIES
        • Table BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2016–2023 (USD MILLION)
      • FOLLITROPIN
        • Table BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2016–2023 (USD MILLION)
    • RECOMBINANT PEPTIDES
      • Table BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
      • Table BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY REGION, 2016–2023 (USD MILLION)
      • GLUCAGON
        • Table BIOSIMILARS MARKET FOR GLUCAGON, BY REGION, 2016–2023 (USD MILLION)
      • CALCITONIN
        • Table BIOSIMILARS MARKET FOR CALCITONIN, BY REGION, 2016–2023 (USD MILLION)
  • BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING
    • INTRODUCTION
      • Table BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
    • IN-HOUSE MANUFACTURING
      • Table BIOSIMILARS MARKET FOR IN-HOUSE MANUFACTURING, BY REGION, 2016–2023 (USD BILLION)
    • CONTRACT MANUFACTURING
      • Table BIOSIMILARS MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2016–2023 (USD MILLION)
  • BIOSIMILARS MARKET, BY DISEASE
    • INTRODUCTION
      • Table BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
    • ONCOLOGY
      • Table BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2016–2023 (USD MILLION)
    • CHRONIC DISEASES
      • Table BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2016–2023 (USD MILLION)
    • AUTOIMMUNE DISEASES
      • Table BIOSIMILARS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2016–2023 (USD MILLION)
    • BLOOD DISORDERS
      • Table BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2016–2023 (USD MILLION)
    • GROWTH HORMONE DEFICIENCY
      • Table BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2016–2023 (USD MILLION)
    • INFECTIOUS DISEASES
      • Table BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016–2023 (USD MILLION)
    • OTHER DISEASES
      • Table BIOSIMILARS MARKET FOR OTHER DISEASES, BY REGION, 2016–2023 (USD MILLION)
  • BIOSIMILARS MARKET, BY REGION
    • INTRODUCTION
      • Table BIOSIMILARS MARKET, BY REGION, 2016–2023 (USD MILLION)
    • NORTH AMERICA
      • Table NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
      • Table NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
      • Table NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
      • Table NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
      • Table NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016–2023 (USD MILLION)
      • Table NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
      • Table NORTH AMERICA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
      • Table NORTH AMERICA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • US
        • Table LIST OF BIOSIMILARS APPROVED IN THE US
        • Table US: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
        • Table US: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table US: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016–2023 (USD MILLION)
        • Table US: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
        • Table US: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • CANADA
        • Table LIST OF BIOSIMILARS APPROVED IN CANADA
        • Table CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
        • Table CANADA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table CANADA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016–2023 (USD MILLION)
        • Table CANADA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
        • Table CANADA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
        • Table CANADA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
    • EUROPE
      • Table LIST OF BIOSIMILARS APPROVED IN EUROPE
      • Table EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
      • Table EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
      • Table EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
      • Table EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
      • Table EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
      • Table EUROPE: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
      • Table EUROPE: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • GERMANY
        • Table GERMANY: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
        • Table GERMANY: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table GERMANY: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
        • Table GERMANY: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
        • Table GERMANY: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • FRANCE
        • Table FRANCE: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
        • Table FRANCE: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table FRANCE: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
        • Table FRANCE: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
        • Table FRANCE: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • UK
        • Table LIST OF BIOSIMILARS IN THE UK
        • Table UK: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
        • Table UK: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table UK: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
        • Table UK: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
        • Table UK: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • ITALY
        • Table ITALY: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
        • Table ITALY: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table ITALY: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
        • Table ITALY: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
        • Table ITALY: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • SPAIN
        • Table SPAIN: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
        • Table SPAIN: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table SPAIN: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
        • Table SPAIN: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
        • Table SPAIN: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • REST OF EUROPE
        • Table ROE: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
        • Table ROE: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table ROE: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
        • Table ROE: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
        • Table ROE: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
    • ASIA
      • Table ASIA: BIOSIMILARS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
      • Table ASIA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
      • Table ASIA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
      • Table ASIA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE, 2016–2023 (USD MILLION)
      • Table ASIA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
      • Table ASIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016–2023 (USD MILLION)
      • Table ASIA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
      • Table ASIA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
      • Table ASIA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • INDIA
        • Table BIOLOGICS APPROVED AND MARKETED IN INDIA
        • Table INDIA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
        • Table INDIA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table INDIA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE, 2016–2023 (USD MILLION)
        • Table INDIA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016–2023 (USD MILLION)
        • Table INDIA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
        • Table INDIA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
        • Table INDIA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • CHINA
        • Table CHINA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
        • Table CHINA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table CHINA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE, 2016–2023 (USD MILLION)
        • Table CHINA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016–2023 (USD MILLION)
        • Table CHINA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
        • Table CHINA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
        • Table CHINA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • SOUTH KOREA
        • Table LIST OF BIOSIMILARS APPROVED IN SOUTH KOREA
        • Table SOUTH KOREA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
        • Table SOUTH KOREA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table SOUTH KOREA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016–2023 (USD MILLION)
        • Table SOUTH KOREA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
        • Table SOUTH KOREA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • JAPAN
        • Table LIST OF BIOSIMILARS APPROVED IN JAPAN
        • Table JAPAN: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
        • Table JAPAN: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table JAPAN: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016–2023 (USD MILLION)
        • Table JAPAN: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
        • Table JAPAN: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
        • Table JAPAN: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • REST OF ASIA
        • Table ROA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
        • Table ROA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table ROA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE, 2016–2023 (USD MILLION)
        • Table ROA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
        • Table ROA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016–2023 (USD MILLION)
        • Table ROA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
        • Table ROA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
        • Table ROA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
    • REST OF THE WORLD (ROW)
      • Table ROW: BIOSIMILARS MARKET, BY REGION, 2016–2023 (USD MILLION)
      • Table ROW: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
      • Table ROW: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
      • Table ROW: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION)
      • Table ROW: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016–2023 (USD MILLION)
      • Table ROW: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION)
      • Table ROW: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION)
      • LATIN AMERICA
        • Table LIST OF SIMILAR BIOTHERAPEUTIC PRODUCTS APPROVED IN LATIN AMERICA
        • Table LATIN AMERICA : BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
      • PACIFIC AND OCEANIA
        • Table LIST OF BIOSIMILARS APPROVED IN AUSTRALIA
        • Table LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND
        • Table PACIFIC AND OCEANIA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
      • MIDDLE EAST AND AFRICA
        • Table MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
  • COMPETITIVE LANDSCAPE
    • OVERVIEW
    • MARKET SHARE ANALYSIS, 2016
    • COMPETITIVE SCENARIO
      • PRODUCT LAUNCHES AND PRODUCT APPROVALS
      • PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
      • ACQUISITIONS
      • EXPANSIONS
  • COMPANY PROFILES
    • SANDOZ
      • OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS (2015–JANUARY 2018)
      • MNM VIEW
    • PFIZER
      • OVERVIEW
      • PRODUCTS OFFERED
        • Table THE COMPANY'S BIOSIMILAR IN PIPELINE ARE LISTED BELOW
      • RECENT DEVELOPMENTS (2015–JANUARY 2018)
      • MNM VIEW
    • TEVA PAHRMACEUTICAL
      • OVERVIEW
      • PRODUCTS OFFERED
        • Table THE COMPANY'S BIOSIMILAR IN PIPELINE ARE LISTED BELOW
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • CELLTRION
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
        • Table THE COMPANY'S BIOSIMILAR IN PIPELINE ARE LISTED BELOW
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • BIOCON
      • OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • AMGEN
      • OVERVIEW
      • PRODUCTS OFFERED
        • Table THE COMPANY'S BIOSIMILAR IN PIPELINE ARE LISTED BELOW
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • SAMSUNG BIOLOGICS
      • OVERVIEW
      • PRODUCTS OFFERED
        • Table THE COMPANY'S BIOSIMILAR IN PIPELINE ARE LISTED BELOW
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • MYLAN
      • OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • DR. REDDY'S LABORATORIES
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • STADA ARZNEIMITTEL AG
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
  • APPENDIX
    • INSIGHTS OF INDUSTRY EXPERTS
    • DISCUSSION GUIDE
    • KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
    • INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
    • AVAILABLE CUSTOMIZATIONS
    • RELATED REPORTS
    • AUTHOR DETAILS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report